-
1
-
-
84894738679
-
In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET
-
Lin S.C., Lin K.J., Hsiao I.T., Hsieh C.J., Lin W.Y., Lu C.S., et al. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. J. Nucl. Med. 2014, 55(1):73-79.
-
(2014)
J. Nucl. Med.
, vol.55
, Issue.1
, pp. 73-79
-
-
Lin, S.C.1
Lin, K.J.2
Hsiao, I.T.3
Hsieh, C.J.4
Lin, W.Y.5
Lu, C.S.6
-
2
-
-
67650465588
-
Visualizing vesicular dopamine dynamics in Parkinson's disease
-
de la Fuente-Fernández R., Sossi V., McCormick S., Schulzer M., Ruth T.J., Stoessl A.J. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 2009, 63(8):713-716.
-
(2009)
Synapse
, vol.63
, Issue.8
, pp. 713-716
-
-
de la Fuente-Fernández, R.1
Sossi, V.2
McCormick, S.3
Schulzer, M.4
Ruth, T.J.5
Stoessl, A.J.6
-
3
-
-
18844471416
-
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
-
Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47(4):493-503.
-
(2000)
Ann. Neurol.
, vol.47
, Issue.4
, pp. 493-503
-
-
Lee, C.S.1
Samii, A.2
Sossi, V.3
Ruth, T.J.4
Schulzer, M.5
Holden, J.E.6
-
4
-
-
33646078787
-
Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography
-
Ginovart N., Galineau L., Willeit M., Mizrahi R., Bloomfield P.M., Seeman P., et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J. Neurochem. 2006, 97(4):1089-1103.
-
(2006)
J. Neurochem.
, vol.97
, Issue.4
, pp. 1089-1103
-
-
Ginovart, N.1
Galineau, L.2
Willeit, M.3
Mizrahi, R.4
Bloomfield, P.M.5
Seeman, P.6
-
5
-
-
81055144433
-
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease
-
Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., McKenzie J., et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011, 134(Pt 11):3290-3298.
-
(2011)
Brain
, vol.134
, pp. 3290-3298
-
-
Nandhagopal, R.1
Kuramoto, L.2
Schulzer, M.3
Mak, E.4
Cragg, J.5
McKenzie, J.6
-
6
-
-
20444477480
-
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
-
Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128(Pt 6):1314-1322.
-
(2005)
Brain
, vol.128
, pp. 1314-1322
-
-
Remy, P.1
Doder, M.2
Lees, A.3
Turjanski, N.4
Brooks, D.5
-
7
-
-
77955844658
-
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study
-
Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40(1):216-221.
-
(2010)
Neurobiol. Dis.
, vol.40
, Issue.1
, pp. 216-221
-
-
Politis, M.1
Wu, K.2
Loane, C.3
Kiferle, L.4
Molloy, S.5
Brooks, D.J.6
-
8
-
-
0347385143
-
Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study
-
Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60(12):1745-1748.
-
(2003)
Arch. Neurol.
, vol.60
, Issue.12
, pp. 1745-1748
-
-
Bohnen, N.I.1
Kaufer, D.I.2
Ivanco, L.S.3
Lopresti, B.4
Koeppe, R.A.5
Davis, J.G.6
-
9
-
-
73449090105
-
History of falls in Parkinson disease is associated with reduced cholinergic activity
-
Bohnen N.I., Muller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73(20):1670-1676.
-
(2009)
Neurology
, vol.73
, Issue.20
, pp. 1670-1676
-
-
Bohnen, N.I.1
Muller, M.L.2
Koeppe, R.A.3
Studenski, S.A.4
Kilbourn, M.A.5
Frey, K.A.6
-
10
-
-
77952998970
-
Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease
-
Bohnen N.I., Muller M.L., Kotagal V., Koeppe R.A., Kilbourn M.A., Albin R.L., et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010, 133(Pt 6):1747-1754.
-
(2010)
Brain
, vol.133
, pp. 1747-1754
-
-
Bohnen, N.I.1
Muller, M.L.2
Kotagal, V.3
Koeppe, R.A.4
Kilbourn, M.A.5
Albin, R.L.6
-
11
-
-
84860122434
-
Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease
-
Kotagal V., Albin R.L., Muller M.L., Koeppe R.A., Chervin R.D., Frey K.A., et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 2012, 71(4):560-568.
-
(2012)
Ann. Neurol.
, vol.71
, Issue.4
, pp. 560-568
-
-
Kotagal, V.1
Albin, R.L.2
Muller, M.L.3
Koeppe, R.A.4
Chervin, R.D.5
Frey, K.A.6
-
12
-
-
84927973245
-
Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET
-
Gjerløff T., Fedorova T., Knudsen K., Munk O.L., Nahimi A., Jacobsen S., et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 2015, 138(Pt 3):653-663.
-
(2015)
Brain
, vol.138
, pp. 653-663
-
-
Gjerløff, T.1
Fedorova, T.2
Knudsen, K.3
Munk, O.L.4
Nahimi, A.5
Jacobsen, S.6
-
13
-
-
84871945993
-
Metabolic brain networks in translational neurology: concepts and applications
-
Niethammer M., Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann. Neurol. 2012, 72(5):635-647.
-
(2012)
Ann. Neurol.
, vol.72
, Issue.5
, pp. 635-647
-
-
Niethammer, M.1
Eidelberg, D.2
-
14
-
-
84907016741
-
Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers
-
Shah M., Seibyl J., Cartier A., Bhatt R., Catafau A.M. Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers. J. Nucl. Med. 2014 Sep, 55(9):1397-1400.
-
(2014)
J. Nucl. Med.
, vol.55
, Issue.9
, pp. 1397-1400
-
-
Shah, M.1
Seibyl, J.2
Cartier, A.3
Bhatt, R.4
Catafau, A.M.5
-
15
-
-
84873564460
-
Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent
-
Bagchi D.P., Yu L., Perlmutter J.S., Xu J., Mach R.H., Tu Z., et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One 2013, 8(2):e55031.
-
(2013)
PLoS One
, vol.8
, Issue.2
, pp. e55031
-
-
Bagchi, D.P.1
Yu, L.2
Perlmutter, J.S.3
Xu, J.4
Mach, R.H.5
Tu, Z.6
-
16
-
-
84931955275
-
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review
-
Petrou M., Dwamena B.A., Foerster B.R., MacEachern M.P., Bohnen N.I., Müller M.L., et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov. Disord. 2015, 30(7):928-935.
-
(2015)
Mov. Disord.
, vol.30
, Issue.7
, pp. 928-935
-
-
Petrou, M.1
Dwamena, B.A.2
Foerster, B.R.3
MacEachern, M.P.4
Bohnen, N.I.5
Müller, M.L.6
-
17
-
-
84918508733
-
Tau imaging: early progress and future directions
-
Villemagne V.L., Fodero-Tavoletti M.T., Masters C.L., Rowe C.C. Tau imaging: early progress and future directions. Lancet Neurol. 2015, 14(1):114-124.
-
(2015)
Lancet Neurol.
, vol.14
, Issue.1
, pp. 114-124
-
-
Villemagne, V.L.1
Fodero-Tavoletti, M.T.2
Masters, C.L.3
Rowe, C.C.4
-
18
-
-
84896840327
-
The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia
-
Compta Y., Parkkinen L., Kempster P., Selikhova M., Lashley T., Holton J.L., et al. The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener. Dis. 2014, 13(2-3):154-156.
-
(2014)
Neurodegener. Dis.
, vol.13
, Issue.2-3
, pp. 154-156
-
-
Compta, Y.1
Parkkinen, L.2
Kempster, P.3
Selikhova, M.4
Lashley, T.5
Holton, J.L.6
-
19
-
-
62549133546
-
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
-
Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8(4):382-397.
-
(2009)
Lancet Neurol.
, vol.8
, Issue.4
, pp. 382-397
-
-
Hirsch, E.C.1
Hunot, S.2
-
20
-
-
13144258735
-
Microglial activation and dopamine terminal loss in early Parkinson's disease
-
Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57(2):168-175.
-
(2005)
Ann. Neurol.
, vol.57
, Issue.2
, pp. 168-175
-
-
Ouchi, Y.1
Yoshikawa, E.2
Sekine, Y.3
Futatsubashi, M.4
Kanno, T.5
Ogusu, T.6
-
21
-
-
30744472146
-
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
-
Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21(2):404-412.
-
(2006)
Neurobiol. Dis.
, vol.21
, Issue.2
, pp. 404-412
-
-
Gerhard, A.1
Pavese, N.2
Hotton, G.3
Turkheimer, F.4
Es, M.5
Hammers, A.6
-
22
-
-
28544434193
-
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation
-
Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128(Pt 12):2777-2785.
-
(2005)
Brain
, vol.128
, pp. 2777-2785
-
-
Adams, J.R.1
van Netten, H.2
Schulzer, M.3
Mak, E.4
McKenzie, J.5
Strongosky, A.6
-
23
-
-
38949140887
-
Positron emission tomography in premotor Parkinson's disease
-
Stoessl A.J. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl 3):S421-S424.
-
(2007)
Parkinsonism Relat. Disord.
, vol.13
, pp. S421-S424
-
-
Stoessl, A.J.1
-
24
-
-
84896403898
-
MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review
-
Sakakibara R., Tateno F., Kishi M., Tsuyusaki Y., Terada H., Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat. Disord. 2014, 20(3):267-273.
-
(2014)
Parkinsonism Relat. Disord.
, vol.20
, Issue.3
, pp. 267-273
-
-
Sakakibara, R.1
Tateno, F.2
Kishi, M.3
Tsuyusaki, Y.4
Terada, H.5
Inaoka, T.6
-
25
-
-
70350678559
-
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study
-
Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132(Pt 11):2970-2979.
-
(2009)
Brain
, vol.132
, pp. 2970-2979
-
-
Nandhagopal, R.1
Kuramoto, L.2
Schulzer, M.3
Mak, E.4
Cragg, J.5
Lee, C.S.6
-
26
-
-
79955466566
-
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease
-
de la Fuente-Fernandez R., Schulzer M., Kuramoto L., Cragg J., Ramachandiran N., Au W.L., et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann. Neurol. 2011, 69(5):803-810.
-
(2011)
Ann. Neurol.
, vol.69
, Issue.5
, pp. 803-810
-
-
de la Fuente-Fernandez, R.1
Schulzer, M.2
Kuramoto, L.3
Cragg, J.4
Ramachandiran, N.5
Au, W.L.6
-
27
-
-
84920771791
-
Central pharmacokinetics of levodopa: lessons from imaging studies
-
Stoessl A.J. Central pharmacokinetics of levodopa: lessons from imaging studies. Mov. Disord. 2015, 30(1):73-79.
-
(2015)
Mov. Disord.
, vol.30
, Issue.1
, pp. 73-79
-
-
Stoessl, A.J.1
-
28
-
-
84896751626
-
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients
-
Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J. Clin. Invest. 2014, 124(3):1340-1349.
-
(2014)
J. Clin. Invest.
, vol.124
, Issue.3
, pp. 1340-1349
-
-
Politis, M.1
Wu, K.2
Loane, C.3
Brooks, D.J.4
Kiferle, L.5
Turkheimer, F.E.6
-
29
-
-
79953647380
-
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
-
Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., Hotton G., et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011, 134(Pt 4):979-986.
-
(2011)
Brain
, vol.134
, pp. 979-986
-
-
Ahmed, I.1
Bose, S.K.2
Pavese, N.3
Ramlackhansingh, A.4
Turkheimer, F.5
Hotton, G.6
-
30
-
-
79958163183
-
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
-
Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76(21):1811-1816.
-
(2011)
Neurology
, vol.76
, Issue.21
, pp. 1811-1816
-
-
Ramlackhansingh, A.F.1
Bose, S.K.2
Ahmed, I.3
Turkheimer, F.E.4
Pavese, N.5
Brooks, D.J.6
|